newsfilter
← Latest News
GlobeNewswire·

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

First vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial Anticipate topline Phase 1b data in mid-2023 BRIDGEWATER, N.J., March 09, 2023 (GLOBE